STOCK TITAN

Evotec Ag - EVO STOCK NEWS

Welcome to our dedicated page for Evotec news (Ticker: EVO), a resource for investors and traders seeking the latest updates and insights on Evotec stock.

About Evotec AG

Evotec AG (symbol: EVO) is a globally recognized life sciences company that excels in drug discovery and development, delivering comprehensive solutions for pharmaceutical, biotechnology, and academic partners. With a highly synergistic multimodality platform, Evotec integrates advanced technologies, robust data analytics, and innovative scientific approaches to facilitate the discovery, development, and production of both first-in-class and best-in-class therapeutics.

Comprehensive Business Model

Evotec operates through a unique business model characterized by:

  • Shared R&D Services: Providing tailored drug discovery and manufacturing services on a fee-for-service basis, this segment forms the core of their operations and fuels a significant portion of their revenues.
  • Collaborative Partnerships: Engaging in co-creation partnerships with Top 20 Pharma companies, over 800 biotechnology firms, academic institutions, and nonprofit organizations, Evotec extends its reach across a broad spectrum of therapeutic areas.
  • CDMO and Biologics: Through its Just-Evotec Biologics segment, the company offers specialized contract development and manufacturing operations, particularly in the biologics arena, ensuring high-quality production capabilities.

This diversified model emphasizes strategic alliances, allowing the company to efficiently bridge academic research and commercial development, thereby accelerating the path from bench to bedside.

Innovative Therapeutic Focus

Evotec is renowned for its dedication to addressing unmet medical needs across a variety of therapeutic areas. Key focus areas include:

  • Central nervous system disorders
  • Oncology and metabolic diseases
  • Inflammation and infectious diseases
  • Women's health
  • Emerging areas such as stem cell-based therapies and precision medicine

Each area is supported by a robust research and development structure, where Evotec leverages proprietary assets alongside collaborative research initiatives to push the boundaries of modern medicine.

Global Operational Footprint

Headquartered in Hamburg, Germany, Evotec maintains a strong global presence with production and R&D sites strategically located across Europe and the United States. This international network not only enhances efficiency in operations but also ensures the company can tap into diverse scientific expertise and market dynamics.

Commitment to Excellence and Expertise

Evotec's commitment to quality and innovation is mirrored by its extensive portfolio of co-owned and proprietary research projects, spanning the full spectrum of drug development — from early discovery through to clinical development. By fostering an environment of collaborative excellence and incorporating state-of-the-art technologies, the company continuously reinforces its standing in the competitive pharmaceutical services sector.

Position within the Competitive Landscape

In an industry where precision and innovation are paramount, Evotec distinguishes itself through its integrated approach and proven track record of successful partnerships. The company’s ability to adapt its service offerings to meet evolving client needs and cutting-edge scientific challenges positions it as a formidable partner for stakeholders across the biopharmaceutical spectrum. Its operational excellence and commitment to groundbreaking research underscore a strategic focus on delivering high-quality therapeutic solutions without speculative projections or promotional language.

Conclusion

Evotec AG exemplifies a well-structured, innovative, and collaborative approach to advancing pharmaceutical research. Its robust service offerings, global presence, and diversified therapeutic portfolio provide invaluable insights for investors seeking to understand the dynamics of the life sciences sector. By maintaining a clear focus on strategic R&D initiatives and forming key alliances, Evotec continues to drive progress in the field of drug discovery and development.

Rhea-AI Summary

Evotec announced a collaboration with the University of Bristol to enhance its molecular patient database focusing on nephrotic syndrome. This partnership grants Evotec access to an international cohort's longitudinal clinical data and biospecimens from hundreds of patients across Asia, India, and Africa. Evotec plans to utilize its multi-omics platforms, EVO panOmics and EVO panHunter, to identify disease mechanisms and diagnostic markers, aiming for new targeted therapies. This collaboration could significantly impact treatment options for nephrotic syndrome patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
none
-
Rhea-AI Summary

Evotec SE (NASDAQ: EVO) has made an equity investment in IMIDomics, Inc., a biotechnology firm focusing on treatments for immune-mediated inflammatory diseases (IMIDs). The investment will allow Evotec to participate in IMIDomics' board of directors while supporting the advancement of its Precision Discovery™ Engine. This initiative integrates patient biological data and clinical expertise to identify effective treatments for over 17,000 IMID patients. The collaboration aims to develop targeted medicines addressing unmet medical needs in the field.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.87%
Tags
none
-
Rhea-AI Summary

Evotec SE announced that Bayer has discontinued the development of eliapixant (BAY1817080), an investigational P2X3 receptor antagonist. Bayer determined that the risks outweigh the benefits after reviewing the available data. As a result, Evotec regains rights to all P2X3 assets and will evaluate the data and options moving forward. The company states that this change does not affect its strategic goals outlined in the Action Plan 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.07%
Tags
Rhea-AI Summary

Evotec SE announced a partnership with Boehringer Ingelheim focusing on induced pluripotent stem cell (iPSC)-based disease modeling for ophthalmologic disorders. This collaboration aims to identify and validate therapeutic targets through phenotypic screening and Evotec's PanOmics platform, addressing a significant unmet need in vision-related diseases. The partnership includes undisclosed upfront payments and ongoing royalties for successful therapeutic development. Dr. Cord Dohrmann highlighted the potential of their unique methodologies to deliver effective drugs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
partnership
-
Rhea-AI Summary

Evotec SE has announced a drug discovery collaboration with Eli Lilly focusing on metabolic diseases, particularly kidney diseases and diabetes. This partnership will leverage Evotec's extensive kidney disease patient database and metabolic expertise to identify novel therapeutic targets. Over three years, Lilly can select up to five programs, potentially generating up to $1 billion in total value for Evotec, including milestone payments and royalties. This collaboration underscores Evotec's commitment to innovative drug development in underserved therapeutic areas.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
none
-
Rhea-AI Summary

Evotec has expanded its collaboration with Bristol Myers Squibb to target neurodegenerative diseases like Alzheimer's through a novel protein degradation strategy. This expansion includes a payment of US$ 15 million from Bristol Myers Squibb. The partnership, initiated in December 2016, aims to discover disease-modifying treatments using Evotec's advanced patient-derived disease models. Dr. Cord Dohrmann highlighted the collaboration's productivity and commitment to innovative drug targeting mechanisms, addressing the significant unmet medical need in treating neurodegenerative conditions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
none
Rhea-AI Summary

Evotec announced it has received a €7.5 million grant from the German Federal Ministry of Education and Research to develop EVT075, a potential first-in-class immunomodulatory therapy targeting COVID-19. This funding aims to facilitate clinical studies assessing the safety and efficacy of the compound, which has shown promising results against SARS-CoV-2 in pre-clinical studies. The therapy aims to amplify the immune response and reduce hospitalizations related to COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.22%
Tags
covid-19
-
Rhea-AI Summary

Evotec SE has received an $18 million grant from the Bill & Melinda Gates Foundation to support a fully integrated drug discovery program targeting women's health and contraceptive technology. The project will utilize Evotec's advanced drug discovery platforms and AI/ML tools to develop a first-in-class program, taking it from concept to pre-clinical development. Dr. Craig Johnstone, COO of Evotec, expressed excitement about the potential impact of the project on women's health and the trust placed in their capabilities by the Gates Foundation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.02%
Tags
none
-
Rhea-AI Summary

EQRx has partnered with Evotec to leverage its data-driven drug discovery platform to enhance EQRx's pipeline focused on oncology and immunology. This collaboration aims to accelerate the development of innovative, affordable medicines. EQRx will focus on clinical development while Evotec will lead drug discovery and pre-clinical development. Additionally, Evotec will gain from potential profits through a profit-sharing mechanism. This partnership aligns with EQRx's mission to provide cost-effective therapies and follows its proposed merger with CM Life Sciences III, expected to complete in Q4 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
partnership
Rhea-AI Summary

Evotec and EQRx announced a strategic partnership to utilize Evotec's data-driven drug discovery platform aimed at developing affordable medicines. This collaboration will expedite EQRx's pipeline in oncology and immunology, with Evotec leading the drug discovery and pre-clinical efforts, while EQRx handles clinical development and commercialization. The partnership also includes a variable profit share for Evotec from successful asset development. This alliance aligns with EQRx's commitment to provide innovative therapies at lower costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.33%
Tags
partnership

FAQ

What is the current stock price of Evotec (EVO)?

The current stock price of Evotec (EVO) is $3.34 as of April 1, 2025.

What is the market cap of Evotec (EVO)?

The market cap of Evotec (EVO) is approximately 1.2B.

What is Evotec AG's core business model?

Evotec AG operates through a dual approach, offering fee-for-service drug discovery and manufacturing services alongside collaborative partnerships in R&D and biologics CDMO operations.

In which therapeutic areas does Evotec specialize?

The company is active in multiple areas including central nervous system disorders, oncology, metabolic diseases, inflammation, infectious diseases, and emerging fields such as stem cell-based therapies.

How does Evotec generate revenue?

Revenue is largely generated through its shared R&D services on a fee-for-service basis and through contract development and manufacturing, particularly in the biologics sector.

What makes Evotec a significant player in the pharmaceutical services industry?

Evotec’s strength lies in its integrated platform, robust global presence, and strong network of strategic partnerships with major pharmaceutical companies, biotech firms, and academic institutions.

Where is Evotec headquartered and what is its global footprint?

Headquartered in Hamburg, Germany, Evotec has multiple production and research sites across Europe and the United States, ensuring comprehensive global operations.

How does Evotec enhance its R&D capabilities?

The company leverages a combination of internally developed assets and external collaborations to drive innovation, ensuring a robust pipeline from early discovery to clinical development.

What role do strategic partnerships play in Evotec's operations?

Strategic partnerships allow Evotec to co-create innovative therapies and expand its service offerings, enabling efficient translation of scientific research into therapeutic solutions.
Evotec Ag

OTC:EVO

EVO Rankings

EVO Stock Data

1.18B
354.61M
2.52%
0.19%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Germany
Hamburg